RxDoctor Payments Data

Michael Martinez

Optometrist · Providence, RINPI 1770924565

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 98 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 14 manufacturers, the largest accounting for just 20.3% — the pattern of someone who eats at a lot of different presentations.

$2,269in general payments, 2019–2025

Across 98 payments — averaging $23.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Coopervision Inc.$461
  • AbbVie$412
  • Alcon$327
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$271
  • Bausch & Lomb Americas Inc.$236
  • Tarsus Pharmaceuticals, Inc.$170
  • plus $392 from 8 others

What the payments were for

  • Food & beverage$2,269100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,269 in reported general payments places this provider in the 85th percentile of 226 optometrist providers in Rhode Island.

See all optometrist providers in Rhode Island

Medicare billing

Part B allowed, 2024
$39,772
Medicare patients
197
Services billed
1,393

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost17$7,200
RocklatanNetarsudil Mesylat/Latanoprost14$5,299
Latanoprost203$3,019
SimbrinzaBrinzolamide/Brimonidine Tart12$2,366
Brimonidine Tartrate17$2,000
Prednisolone Acetate26$844
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat27$619
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha35$412
Timolol Maleate33$268

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan$412$7,20017 claims
AlconSimbrinza$327$2,36612 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 226 optometrist providers in Rhode Island.

Other optometrist in Providence

See the full list for Rhode Island

Where these figures come from

Is this you, or does something look wrong? →